Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice

Xiaomeng Hu, Karl Manner, Rowena DeJesus, Kathy White, Corie Gattis, Priscilla Ngo, Christopher Bandoro, Eleonore Tham, Elaine Y. Chu, Chi Young, Frank Wells, Ronald Basco, Annabelle Friera, Divy Kangeyan, Pascal Beauchesne, William E. Dowdle, Tobias Deuse, Terry J. Fry, Aaron E. Foster and Sonja Schrepfer ()
Additional contact information
Xiaomeng Hu: Sana Biotechnology Inc.
Karl Manner: Sana Biotechnology Inc.
Rowena DeJesus: Sana Biotechnology Inc.
Kathy White: Sana Biotechnology Inc.
Corie Gattis: Sana Biotechnology Inc.
Priscilla Ngo: Sana Biotechnology Inc.
Christopher Bandoro: Sana Biotechnology Inc.
Eleonore Tham: Sana Biotechnology Inc.
Elaine Y. Chu: Sana Biotechnology Inc.
Chi Young: Sana Biotechnology Inc.
Frank Wells: Sana Biotechnology Inc.
Ronald Basco: Sana Biotechnology Inc.
Annabelle Friera: Sana Biotechnology Inc.
Divy Kangeyan: Sana Biotechnology Inc.
Pascal Beauchesne: Sana Biotechnology Inc.
William E. Dowdle: Sana Biotechnology Inc.
Tobias Deuse: University of California San Francisco
Terry J. Fry: Sana Biotechnology Inc.
Aaron E. Foster: Sana Biotechnology Inc.
Sonja Schrepfer: Sana Biotechnology Inc.

Nature Communications, 2023, vol. 14, issue 1, 1-14

Abstract: Abstract Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all. Although current allogeneic CAR products have the potential to overcome manufacturing bottlenecks, they are subject to immune rejection and failure to persist in the host, and thus do not provide the same level of efficacy as their autologous counterparts. Here, we aimed to develop universal allogeneic CAR T cells that evade the immune system and produce a durable response. We generated human hypoimmune (HIP) T cells with disrupted B2M, CIITA, and TRAC genes using CRISPR-Cas9 editing. In addition, CD47 and anti-CD19 CAR were expressed using lentiviral transduction. These allogeneic HIP CD19 CAR T cells were compared to allogeneic CD19 CAR T cells that only expressed the anti-CD19 CAR (allo CAR T). In vitro assays for cancer killing and exhaustion revealed no differences between allo CAR T and HIP CAR T cells, confirming that the HIP edits did not negatively affect T cell performance. Clearance of CD19+ tumors by HIP CAR T cells in immunodeficient NSG mice was comparable to that of allo CAR T cells. In fully immunocompetent humanized mice, HIP CAR T cells significantly outperformed allo CAR T cells, showed improved persistence and expansion, and provided lasting cancer clearance. Furthermore, CD47-targeting safety strategies reliably and specifically eliminated HIP CAR T cells. These findings suggest that universal allogeneic HIP CAR T cell-based therapeutics might overcome the limitations associated with poor persistence of allogeneic CAR T cells and exert durable anti-tumor responses.

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-37785-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-37785-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-37785-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().